Jefferies Discusses Elan Corp (ELN) After 2012 Global Healthcare Conference

Article Stock Quotes (1) Comments (0)

Jefferies commented on Elan Corp (NYSE: ELN) following the Jefferies 2012 Global Healthcare Conference, where CEO Kelly Martin presented.

The firm comments, "Investor interest in ELN is at an all time high with the imminent bapineuzumab Ph.3 Alzheimer's data -- one of the most important data events in the entire industry. ELN can't comment on Bapi, but reiterated its confidence in Tysabri growth (easily a >$3B product w/ 20% market share). Thus we continue to believe Bapi is upside to the valuation."

The firm maintained their Buy rating and price target of $20.00

For an analyst ratings summary and ratings history on Elan Corp click here. For more ratings news on Elan Corp click here.

Shares of Elan Corp closed at $13.43 yesterday, with a 52 week range of $8.58-$15.27.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Morgan Stanley Says Tesla (TSLA) 'Top Pick in U.S. Autos'
• Deutsche Bank Takes Aegerion (AEGR) Price Target from $52 to $85
• Elan Announces Publication of Response Document

Create E-mail Alert Related Categories

Analyst Comments

Related Entities

Jefferies & Co

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?